Armenija - angleščina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - poliovirus types 1, poliovirus types 3 - suspension oral - not less than-106ccid50/dose+ not less than-105.8ccid50/dose

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topotecan hydrochloride, quantity: 4 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - for single agent therapy for the treatment of patients with: small cell lung carcinoma, after failure of first line chemotherapy. metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. in combination with cisplatin for the treatment of patients with: histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - mycobacterium bovis (bacillus calmette and guerin (bcg) strain), quantity: 1.5 mg - injection, powder for - excipient ingredients: monosodium glutamate monohydrate - bcg vaccine is recommended for active immunisation in high risk groups. the nhmrc recommendation for bcg vaccination are: bcg is recommended for use in 3 groups of infants: . aboriginal and torres strait islander neonates in regions of high incidence; . neonates born to patients with leprosy; . children under the age of 5 years who will be travelling to live in countries of high tuberculosis prevalence for long periods. bcg vaccination should be considered for the following children and adolescents: .neonates who will be living in a household which includes immigrants or visitors recently arrived from countries of high prevalence (this also applies to neonates in families who have returned to visit the homes of relatives in countries of high prevalence); . children and adolescents aged less than 16 years who continue to be exposed to a patient with active tuberculosis, and where the child or adolescent cannot be placed on isoniazid therapy or the active case has organisms resistant to both isoniazid and rifampicin. in addition to the above categories, there are other groups of individuals who are at increased risk of tuberculosis, but for whom the value of bcg vaccine is less certain. these groups are: . health care workers with a high risk of exposure to tuberculosis, such as staff of chest clinics and tuberculosis wards, physiotherapists, diagnostic laboratory staff, autopsy room staff, and most medical and nursing staff of public hospitals; . travellers over the age of 5 years who will spend prolonged periods in countries of high tuberculosis prevalence. . a tuberculin test should be performed prior to bcg vaccination in all individuals, except in infants under 6 months of age. only subjects in whom a test dose of 10 units produces less than 5mm of induration should receive bcg. bcg vaccination has no value in the treatment of tuberculosis disease.

Jordanija - angleščina - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الرعاية الدوائية - pharma care drug store - bcg 2 x 10(8)-3x10(9) viable units - 2 x 10(8)-3x10(9) viable units

Uganda - angleščina - National Drug Authority

serum institute of india ltd. - bcg vaccine(freeze dried) - parenteral ordinary dry vials - 1.33*100000 c.f.u/0.1ml

Kenija - angleščina - Pharmacy and Poisons Board

final bulk for onco bcg 40 mg/ml” as the active… - intravesical solution/solution for injection - bacillus calmette-guerin strain: 40 mg/ml - bcg vaccine

Kenija - angleščina - Pharmacy and Poisons Board

statens serum institut 5 artillerivej dk 2300 copenhagen s denmark - bcg vaccine danish strain 1331 - powder and solvent for suspension for injecti - 2-8 x 105 cfu - bacterial vaccines: tuberculosis vaccines

Tanzanija - angleščina - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - bcg vaccine - live, freeze-dried vaccine - 2 x 105 and 8 x 105 cfu/ml

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - bacillus calmette-guerin 500 mcfu (range: 2-8x10e8 cfu) - powder for injection - 500 mcfu - active: bacillus calmette-guerin 500 mcfu (range: 2-8x10e8 cfu) excipient: ammonia solution asparagine citric acid monohydrate dibasic potassium phosphate ferric ammonium citrate glycerol zinc formate lactose magnesium sulfate - oncotice is used as a treatment of flat urothelial cell carcinoma in situ (cis) of the bladder, and as an adjuvant therapy after transurethral resection (tur) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage ta (grade 2 or 3) or t1 (grade 1, 2 or 3). oncotice is only recommended for stage ta grade 1 papillary tumours when there is judged to be a high risk of tumour recurrence.

Malta - angleščina - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - bacillus calmette, gu, rin, bcg - powder and solvent for solution for intravesical use - bacillus calmette-guÉrin (bcg) 2x10^8 to 3x10^8 u - immunostimulants